Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
140 hedge funds and large institutions have $411M invested in Achillion Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 35 reducing their positions, and 39 closing their positions.
321% more call options, than puts
Call options by funds: $6.56M | Put options by funds: $1.56M
71% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 35
14% less funds holding
Funds holding: 162 → 140 (-22)
53% less capital invested
Capital invested by funds: $873M → $411M (-$462M)
54% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 39
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$12.9M |
| 2 |
Morgan Stanley
New York
|
+$10.8M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$9.74M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.51M |
| 5 |
State Street
Boston,
Massachusetts
|
+$7.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$57.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$15.6M |
| 3 |
RI
RTW Investments
New York
|
-$10.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.46M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LTFS
176
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$532 | -100 | -56% |
|
177
US Bancorp
Minneapolis,
Minnesota
| – | +$436 | +82 | New |
|
ACHN Hedge Fund Activity: Q4 2016 in Review
140 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2016, worth a combined $411M — down 53% from $873M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of ACHN and 18 opened new positions — a net loss of 21 holders — while 35 trimmed existing stakes and 60 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $12.9M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $57.1M sold.
- 140 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2016, down from 162 in Q3 2016.
- Funds reported $411M of Achillion Pharmaceuticals stock for Q4 2016, down 53% quarter-over-quarter.
- 18 funds opened new Achillion Pharmaceuticals positions in Q4 2016 and 39 closed out, a net change of -21 holders.
- The largest Achillion Pharmaceuticals buyer in Q4 2016 was BVF Inc, an estimated $12.9M added.
- The largest Achillion Pharmaceuticals seller in Q4 2016 was Point72 Asset Management, an estimated $57.1M sold.
Based on aggregated 13F filings for Q4 2016.